The FDA approved ViiV’s Dovato as a complete, once-daily, single-tablet regimen of dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg for treating HIV-1 infection in adults with no antiretroviral treatment history and no known resistance to either DTG or 3TC.
The U.S. Food and Drug Administration approved ADMA Biologics’ Asceniv to treat primary humoral immunodeficiency disease (PIDD or PI) in adults and adolescents.
The pharmaceutical industry should match its words with action on researching new antibiotics to address the threat posed by drug-resistant superbugs, a former UK government adviser said.
The U.S. Food and Drug Administration approved expanded use of Regeneron Pharmaceuticals Inc. and Sanofi SA’s eczema drug Dupixent to include patients aged between 12 and 17 years.
ViiV Healthcare Presents Positive, 48-Week Data from Two Pivotal Phase III Studies in Adults Living with HIV-1 Infection
ViiV Healthcare presented comprehensive 48-week data from the ATLAS (Antiretroviral Therapy as Long-Acting Suppression) and FLAIR (First Long-Acting Injectable Regimen) pivotal phase III studies of the novel, investigational, long-acting regimen of cabotegravir and rilpivirine.
An HIV-positive man in Britain became the second known adult worldwide to be cleared of the AIDS virus after he received a bone marrow transplant from an HIV resistant donor, his doctors said.
A bacteriophage is a virus that infects bacteria. They are not typically used to treat bacterial infections, but in desperate cases, they have been used to treat particularly antibiotic-resistant infections.
The spread of superbugs resistant to antimicrobial drugs shows no sign of slowing in Europe, health officials said, making food poisoning and other infections more difficult to treat.
Motif Bio plc announced today that the clinical-stage biopharmaceutical company received a complete response letter from the U.S. Food and Drug Administration regarding the new drug application for iclaprim for the treatment of acute bacterial skin and skin structure infections.
Prior infection with dengue, a mosquito-borne disease that infects nearly 400 million people a year, could reduce the risk of contracting Zika nearly by half, U.S. and Brazilian researchers reported.